The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant.

Trial Profile

The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 06 Feb 2014 Top-line results reported in a Shire media release.
    • 06 Feb 2014 Primary endpoint 'Significant superiority of lisdexamfetamine vs placebo in change in score on the Montgomery-Asberg-Depression-Rating-Scale' has not been met, according to a Shire media release.
    • 24 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top